How Organon Expects To Steer Its Women’s Health Engine In India
Executive Summary
Organon commercial director and lead for the South Asia Region, Anjan Sen, lays out how the Merck spin-out expects to scale up activities in markets like India. A mix of new products, targeted repurposing efforts and access-driven pricing are part of the strategy that could potentially see the company double its presence in the region.
You may also be interested in...
CEO Kevin Ali Marks Organon’s Progress In First Post-Spin Year
A year after Organon spun out of Merck, the company has delivered on its financial guidance, generated double-digit biosimilars sales growth and executed six deals to grow in women’s health.
How Ex-Janssen India Chief Is Steering Bharat Serums’ Ambitions In Women’s Health
Sanjiv Navangul, managing director and CEO, Bharat Serums and Vaccines, in a wide-ranging interview with Scrip, outlines the firm’s game plan to establish itself as a “force to reckon with” in women’s health - it goes beyond drugs and encompasses devices and potentially digital therapeutics as well. The former Janssen India chief also weighs in on the worrying industry-wide input cost escalation scenario and supply chain turbulence.
Organon Outlines Importance Of Speed For US Humira Opportunity
At its debut year-end financial earnings call, Organon spoke in further detail about the impending launch of Humira biosimilars, as well as its desire to continue growing its portfolio.